<http://schema.org/articleBody>
"The Supreme Court will soon decide whether generic drug manufacturers can be sued in state court for a drug's design defects after federal officials approved the brand-name version.The justices Tuesday heard arguments from generic manufacturer Mutual Pharmaceutical Co., Inc., which wants a $21 million judgment dismissed.A New Hampshire jury gave that to Plaistow resident Karen Bartlett after she took sulindac, the generic form of the drug Clinoril. It caused at least 60 percent of her skin to deteriorate or burn and permanent near-blindness.\"I just wanted to get the word out that this can happen if you take a medication; a generic drug brand,\" Bartlett said.Bartlett, 53, had to be helped down the steps of the U.S. Supreme Court on Tuesday.She said she took sulindac in 2004 for shoulder pain.Mutual says the award should be dismissed because, as required by federal law, sulindac matched Clinoril in composition.\"One out of a million had a terrible, terrible adverse reaction. Hundreds of thousands are benefiting from the drug,\" Mutual Pharmaceutical Company attorney Jay Lefkowitz said.The company said that should pre-empt the jury's verdict, which found that the generic version was faulty.The impact of the case could be far-reaching into other similar cases.\"I didn't think it would come this far, but if it had to to make people aware, then that's what we had to do,\" Bartlett said.The Court is expected to rule on the case later this year.\u00A0"^^<http://www.w3.org/2001/XMLSchema#string>
<http://www.wmur.com/article/supreme-court-hears-nh-woman-s-claim-against-drug-company/5180322>